Evaluation of proteases from the prolyl oligopeptidases family as targets for drug development.

Projektinformationen

PROLYL OLIGOPEPTIDAS

ID Finanzhilfevereinbarung: QLK3-CT-2000-60031

Projekt abgeschlossen

Startdatum 21 August 2001

Enddatum 20 August 2005

Finanziert unter

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Gesamtkosten € 245 400,00

EU-Beitrag € 245 400,00

Koordiniert durch

PROBIODRUG GESELLSCHAFT FUER ARZNEIMITTELFORSCHUNG MBH
Germany

Ziel

The research training area is the investigation of a possible involvement of proteases from the prolix oligopeptidase family in different path physiological processes aiming on an evaluation as targets for a drug development.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery

Programm/Programme

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thema/Themen

• 1.1.1.-3. - Key action The "Cell factory"

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

BUR - Bursaries, grants, fellowships

Koordinator

PROBIODRUG GESELLSCHAFT FUER ARZNEIMITTELFORSCHUNG MBH

• EU-Beitrag: Keine Daten
• Adresse: Weinbergweg 22 ; 06120 HALLE (SAALE) ; Deutschland
• Gesamtkosten: Keine Daten